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INTRODUCTION 
A number of compounds capable of inhibiting the aggregation of blood platelets have 
been reported in recent years. Synthesized compounds containing the imidazo [4,5-b] 
quinoline-Zone nucleus are a new series of structurally-novel inhibitors of platelet ag- 
gregation (38). These compounds are potent broad-spectrum inhibitors that inhibit platelet 
aggregation caused by thrombin, ADP, and collagen with roughly equal potency (8,15). 
BMY21190 (Fig. 1) inhibits ADP- and collagen-induced aggregation of rabbit platelets 
with an efficacy comparable to prostacyclin (38). BMY21190 may also be capable of 
elevating the cAMP levels within platelets sufficiently to activate the CAMP-dependent 
protein kinase as does BMY20844 (60, Fig. 1). The active catalytic subunit is released by 
the binding of cAMP to the regulatory subunit of the protein kinase and then acts at many 
different steps in the biochemical pathways to inhibit platelet inhibition (13,58,59). 
Agents that elevate platelet cAMP levels, including inhibitors of platelet cAMP phos- 
phodiesterase (PDE) (2,23,38,46,65), are known to inhibit platelet aggregation (21,38, 
40). Platelet aggregation is generally regarded as an important event in the initiation of 
arterial thrombosis. The current interest in inhibitors of CAMP-PDE as therapeutic agents 
has largely arisen from the recognition that there are distinct PDE isozyme families and 
that tissues have different complements of isozymes. 
Nomenclature and subcellular localization of CAMP-PDE isozymes are to be found in 
articles from Beavo’s (4,28) and Weishaar’s laboratories (67,68). BMY20844 and 
BMY21190 have the characteristics of selective type I11 inhibitors of “low Km” one of 
which is high affinity for cAMP (38). The CAMP-PDE type 111 isozyme has been isolated 
from or found in platelets (17,46), cytosolic fractions of bovine cardiac tissue (19), and 
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FIG. 1. The chemical structures of BMY20844 and BMY21190. 
sarcoplasmic reticulum of canine heart muscle (30). This enzyme is also similar to the 
membrane-bound PDE in adipocytes (9), liver (73), and smooth muscle (36,69). The type 
I11 CAMP-PDE isozyme in the heart is the target of a number of agents that cause an 
increase in contractile force (18,24) and a decrease in peripheral vascular resistance in 
addition to inhibition of platelet aggregation (4 1). 
The bipyridine cardiotonics, amrinone and milrinone, also inhibit CAMP-PDE (type 111) 
and thereby the platelet aggregation. Studies in vitro and in vivo with amrinone have 
demonstrated impaired thromboxane A, formation (3 1 3  1,52,66). Aspirin and dipyri- 
damole are not broad-spectrum inhibitors of aggregation. Anagrelide was a very prom- 
ising candidate until its thrombocytopenic action was observed (1). Thus, in an attempt to 
develop other compounds possessing a favorable pharmacological profile, but lacking 
thrombocytopenic side effects, a series of related imidazoquinolines has been synthesized. 
While milrinone, a selective inhibitor of low Km CAMP-PDE, is a potent cardiac stim- 
ulant it did not produce thrombocytopenia in humans suggesting that the side effect was 
not related to inhibition of low Km CAMP-PDE (3). BMY21190 has a coronary vasodi- 
lating effect. There are no reports available with respect to the hemodynamic action of 
BMY21190. It was evaluated for its ability to modify the development of experimental 
thrombosis resulting from anodal current injury (100 p A  for 6 hr) of the intimal surface 
of the left circumflex coronary artery (LCX) in anesthetized dogs (42). This review also 
summarizes the effect of BMY21190 on infarct size in a canine ischemic model that 
underwent a 90-min occlusion and 6-hr reperfusion of the left coronary artery (43). 
CHEMISTRY 
BMY20844 (1,3-dihydro-7,8-dimethyl-2H-imidazo [4,5-b] quinolin-Zone) and one of 
its derivatives, BMY2 1 190 (7-[4-(N-cyclohexyl-N-methylamino)-4-oxobutoxy]-l,3- 
dihydro-2H-imidazo [4,5-b] quinolin-2-one) (Fig. 1) were synthesized by the Bristol- 
Myers Cardiovascular Chemistry Group, Wallingford, CT, USA. Compounds containing 
the imidazo [4,5-b] quinolin-2-one tricyclic nucleus are a new class of potent broad- 
spectrum inhibitors of platelet aggregation (40). These compounds are very insoluble in 
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water. The ring system of the imidazolin-Zone also exhibits a potent intrinsic activity that 
can be improved by introduction of substituents to the benzene ring. BMY20844, the 
prototype of these compounds, was identified as a promising clinical candidate due to its 
in vitro and in vivo potency for inhibition of platelet aggregation similar to analgrelide 
(40). Oral doses of BMY20844 provided protection similar to that of analgrelide in animal 
models of thrombosis. They produced, however, milder inodilating effects. BMY20844 
is associated with much milder increases in ventricular contractile force and heart rate and 
with reductions in blood pressure in anesthetized ferrets and dogs (38). Rabbit heart 
CAMP-PDE isozymes were resolved by ion-exchange chromatography. BMY20844 in- 
hibited only type I11 (a cGMP-inhibitable, low Km, CAMP-specific PDE) with an IC,, 
value of 5 X lo-* M (60). BMY20844 also inhibited canine cardiac sarcoplasmic retic- 
ulum membrane-bound cGMP-inhibitable, low Km, CAMP-specific PDE with virtually 
the same potency as the inhibition of CAMP-PDE in the platelet homogenate (60). In 
washed platelets, BMY20844 elevated CAMP levels and activated the platelet CAMP- 
dependent protein kinase. Introduction of functionalized side chains to this nucleus also 
markedly enhances biological activity, and BMY21190 inhibits ADP- and collagen- 
induced platelet aggregation in vitro with potency comparable to prostacyclin values 
of 1-3 ng/ml). This compound has also been found to be a powerful inodilating agent 
following oral administration in dogs and ferrets, and has prompted a search for potent 
antithrombotic agents of this basic chemical structure (40). 
ANTITHROMBOTIC EFFECTS OF BMY21190 
Low Amperage Electrical Stimulation of Canine LCX Coronary Artery 
BMY2 1190 was evaluated for its ability to modify the development of experimental 
thrombosis resulting from anodal current injury (100 pA for 6 hr) of the intimal surface 
of the left circumflex coronary artery (LCX) in anesthetized dogs (42). As shown in Fig. 
2, distal to the arterial branch and proximal to its first descending branch, 1-2 cm of the 
LCX was isolated from the surrounding tissue by careful blunt dissection. Within this 
isolated region, an electromagnetic flow probe was affixed to the artery for the continuous 
measurement of LCX blood flow. To aid in the insertion of the LCX-stimulating elec- 
trode, the tip of a 25-gauge hypodermic needle was attached to a 28-gauge teflon-coated 
silver wire. This electrode was inserted through the wall of the LCX so that the tip of the 
electrode (2-3 mm) was in contact with the intimal lining of the vessel. The electrode was 
connected in series to a 250,000-ohm potentiometer, a 9-volt nickel-cadmium battery, and 
a digital ammeter (53). The circuit was completed by suturing a disc electrode to a 
subcutaneous region on the chest wall. The stimulating circuit was designed to permit 
constant monitoring and easy adjustment of the direct anodal current delivered to the 
intimal surface of the LCX. After basal hemodynamic measurements were recorded, 
constant infusion of BMY21190 (1 mgkg over 30 min) or an equivalent volume of 
vehicle was delivered via the left jugular cannula. A constant infusion rate of 0.5 mumin 
was maintained by an infusion pump. Thirty minutes after the start of the infusion, 
electrical stimulation of the LCX was initiated at 100 pA via the implanted silver wire 
electrode. Low amperage electrical stimulation of the canine LCX consistently produced 
occlusive coronary artery thrombosis (Fig. 2) (4233). 
Our model, in which intimal injury produced by low-amperage electrical stimulation of 
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FIG. 2. Surgical procedure and anodal current stimulation in the canine heart. Adapted from ref. 42. 
the LCX induces platelet adhesion and secondary recruitment of platelets to form aggre- 
gates, is a realistic simulation of coronary artery thrombus formation. The intimal platelet 
thrombus in our model is stabilized by the incorporation of fibrin into the growing 
thrombotic mass, and this developed thrombus shows morphological (42,53) and com- 
positional characteristics similar to those of human coronary artery thrombi (10,44,53, 
55). Thus, this method of inducing coronary artery thrombosis provides an appropriate 
model for studying the antithrombotic properties of compounds such as BMY21190. 
BMY21190 or its vehicle was administered twice: before stimulation and 3 hr after 
stimulation (Fig. 3). Stimulation of the LCX was continued for 6 hr until LCX decreased 
to zero for at least 2 min (Fig. 3). The dogs were sacrificed by spontaneous or electrically- 
induced fibrillation. The thrombus present at the site of the electrical injury was removed 
from the intimal surface of the LCX and the thrombus wet weight was measured on an 
analytical balance. Values shown in this review are presented as mean 2 SD. 
Occlusive LCX thrombosis is determined primarily on the basis of total cessation (Fig. 
3) of LCX blood flow (42). The time when thrombotic occlusion of the vessel occurs is 
readily determined by continuously monitoring the LCX blood flow. Complete cessation 
of the LCX blood flow occurred after approximately 3.2 hr of stimulation. However, 
signs of developed ischemia were evident as early as 45 min of the stimulation period. At 
this time, a reduction of the left ventricular isometric force in the LCX-perfused region of 
the myocardium, an alternation in the phasic coronary blood flow wave form, and a 
reduction in mean coronary blood flow were evidence that LCX thrombosis was occur- 
ring. After this, ST-segment elevation was recorded by the epicardial electrode situated in 
the LCX-dependent region of the myocardium. The left ventricular force in this region 
was further diminished. Occlusion and reperfusion of the coronary artery were repeated 
throughout the experiment. The earliest complete LCX occlusion by intravascular throm- 
bosis occurred 75 min after the initiation of LCX coronary artery stimulation and termi- 
nated in ventricular fibrillation. Further elevation of the epicardial electrogram ST seg- 
ments occurred as the LCX flow was reduced to zero. Isometric left ventricular contractile 
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FIG. 3. Changes in left circumflex coronary artery blood flow for each dog in the vehicle and BMY21190 ( 1  
mgikg i.v.) treatment groups. Complete cessation of LCX blood flow as a result of thrombotic occlusion of the 
vessel is indicated by lines that intercept the abscissa. Lines that terminate before the 6-hr time point indicate 
spontaneous ventricular fibrillation. Adapted from ref. 42. 
force was markedly reduced in both the ischemic (LCX) and the nonischemic regions. 
Finally, as indicated in Fig. 3, the LCX coronary blood flow of the control animals 
progressively declined over the course of the experiment until it completely ceased. 
Treatment of the animals with BMY21190 at a dose of 1 mgkg i.v. prevented this 
decline. Thus, BMY21190 prolonged the life span of dogs in this coronary ischemic 
model. Furthermore, a second infusion of BMY21190 was able to dilate the coronary 
artery during the anodal current injury (42) (Fig. 3). Time to fist  hyperemia was observed 
significantly earlier in the vehicle as compared with the BMY21190-treated group during 
the LCX stimulation (Table 1). The average thrombotic mass that developed in response 
to intimal injury of the LCX coronary artery was significantly smaller in animals treated 
with BMY21190 than in the control vehicle dogs (Table 1). There was a 67% reduction 
in the incidence of occlusive LCX coronary thrombosis in the BMY2 1190-treated group 
(2 of 6 dogs occluded) as compared with the control vehicle group (6 of 6 dogs occluded) 
during the 6-hr stimulation period. The difference is significant (Fisher’s Exact; p = 
0.03). 
Under the same experimental conditions, BMY20844 induced similar effects to those 
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TABLE 1. Antithrombotic effect of BMY21190 on reactive hyperemic response and thrombus 
size in a canine model of coronary artery thrombosis 
Vehicle 
(n = 6) 
BMY21190 
( I  mglkg i.v.)(n = 6) 
Time to first hyperemia (min) 
Time to occlusion (min) 
Ratio of experiments where at least one 
response occurred 616 
Average number of hyperemia episodes 
per experiment (n) 2.8 f 6.3 
Average hyperemia magnitude (mumin) 42.9 f 31.4 
Thrombus size (me) 19.8 5 8.5 
142.0 f 58.3 
217.5 * 55.9 
~ 
327.5 2 50.6*** 
340.0 f 40.0* 
2/6* 
0.7 f 0.2 
12.5 f 8.6 
2.1 * 0.4*** 
Mean 5 SD. 
*p < 0.05; *** p < 0.001 vs. vehicle. 
Occlusive thrombi formation followed by spontaneous ventricular fibrillation occurred in all 6 of the 6 dogs 
in the vehicle group and in 2 of 6 dogs that received BMY2I 190. The other dogs in the BMY21190 group were 
sacrificed by electrical ventricular fibrillation at 360 min. The average time to complete thrombi occlusion of the 
LCX is included in the data of sacrificed dogs. Adapted from ref. 42. 
of BMY21190 on time to first hyperemia and thrombus size in a dose-dependent manner 
(43) (Table 2). There was a 65% reduction in the incidence of occlusive LCX coronary 
thrombosis in the BMY20844-treated group (3 of 11 dogs occluded) as compared with the 
control vehicle group (7 of 9 dogs occluded). 
Ex vivo Aggregation Study 
Ex vivo aggregometry refers to experiments in which aggregometry was performed in 
vitro on platelet rich plasma (PRP) samples obtained from dogs dosed with BMY21190 
(1 mgkg). Platelet reactivity was assessed in vitro using PRP obtained from venous blood 
collected in 3.8% citrate (1 mYlO ml) before stimulation (prestimulation) and 4 hr after 
stimulation (poststimulation). The blood was centrifuged at 380 X g for 5 min to obtain 
the PRP and again at 2200 X g for 10 min to yield platelet poor plasma (PPP). The PRP 
was adjusted to 200,000 platelets/p,l by adding PPP. Aggregation responses were mea- 
sured within 15 min of PRP preparation using a PAP-3 platelet aggregometer (Bio Data 
Corp., Willow Grove, PA) to record the percentage of change in the light transmission of 
TABLE 2. Antithrombotic eflect of BMY20844 on reactive hyperemic response and thrombus 
size in a canine model of coronary artery thrombosis 
BMY20844 
Vehicle 1 mgkg i.v. 3 mglkg i.v. 
Time to first hyperemia 106.1 IT 63.4 256.0 rt 127.2* 302.0 * 60.8*** 
(rnin) (n = 9) (n = 5) (n = 6) 
Thrombus size 22.5 f 9.0 10.3 t 3.2* 5.4 2 8.9* 
(mg) (n = 9) (n = 5 )  (n = 6) 
Mean 2 SD. 
* p < 0.05; *** p < ,001 vs. vehicle 
Adapted from ref. 44. 
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PRP (set at 0%) relative to PPP (set at 100%). Aggregation was initiated by adding 50 pl 
of either ADP (23.4, 58.5, or 117 pM) (Sigma Chemical Co., St. Louis, MO), collagen 
(1/100, 1/800, or 1/1600) (Ethicon Collagen Dispersion), or arachidonic acid (0.325 or 
0.65 mM) (Sigma Chemical Co., St. Louis, MO) to 450 pl of PRP. A total of eight 
different concentrations of three compounds was tested. Posttreatment responses for each 
animal were compared with the prestimulation responses. The data are shown in Table 3. 
Ex vivo platelet aggregation in response to ADP, arachidonic acid, and collagen was 
significantly inhibited by BMY21190. There were no significant changes in the platelet 
counts after administration of BMY21190. 
Infused at a dose of 1 mg/kg BMY21190 inhibited ex vivo platelet aggregation and 
prevented thrombotic occlusion of the LCX at the site of the electrically induced intimal 
injury. Postmortem examination of the LCX coronary artery revealed that in dogs whose 
LCX coronary blood flow had stopped, intravascular thrombi completely filled the arterial 
lumen. This progressive decline and ultimate cessation of LCX blood flow correlate with 
the complete thrombotic filling of the vascular lumen. The vasodilating properties of 
BMY21190 may play a role in maintaining the LCX blood flow by relaxing vascular tone 
and permitting blood to flow between the arterial wall and the thrombotic mass. 
Under the same conditions, ex vivo platelet aggregation in response to arachdonic acid 
was inhibited significantly by BMY20844 (44). No significant changes were demon- 
strated in the platelet counts after administration of BMY20844 (1 mg/kg i.v.). In rats 
significant inhibition of collagen- and/or ADP-induced aggregation by BMY20844 was 
observed ex vivo two hr after oral administration in a water suspension (8). 
HEMODYNAMIC EFFECTS OF BMY21190 
Effects of BMY21190 in a Canine Model of Coronary Artery Thrombosis 
Hemodynamic data were recorded continuously during the course of the experiment on 
a six-channel Grass polygraph. Arterial blood pressure transducer was attached to a 
polyethylene catheter that was placed in the ascending aorta via the left carotid artery. 
Segmental left ventricular isometric contractile force in the regions of the myocardium 
which depend on the LCX and the left anterior descending coronary artery (LAD) was 
measured with a Brodie-Walton strain gauge arch. 
A summary of the hemodynamic effects of BMY21190 after 30 min of infusion is 
TABLE 3. Effects of BMY21190 (1 .O mglkg i .v . )  on ex vivo aggregation in a canine model of 
coronary artery thrombosis 
Vehicle (n = 8) BMY21190 (n = 6) 
Pre post P'e post 
Platelet aggregation (%) 
ADP (58.5 pM) 50.6 f 20.1 49.3 Ifr 17.5 54.3 t- 27.7 22.5 & 12.5* 
AA (0.65 mM) 51.0 rf- 30.5 54.0 Ifr 30.5 66.0 t- 31.1 8.8 5 7.6* 
Collagen (1:lOO) 61.1 f 8.2 63.0 Ifr 18.7 72.0 t 17.4 23.8 Ifr 23.7* 
Mean rf- SD. 
* p < 0.05 per v. post. 
AA: arachidonic acid. 
Adapted from ref. 42. 
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shown in Table 4. BMY21190 exhibits a pronounced antithrombotic effect when admin- 
istered at a dose of 1 mg/kg i.v. Table 4 also indicates the marked hemodynamic effects 
of BMY21190. Although no significant changes were observed in the double product or 
tension, a reflex elevation of heart rate was demonstrated in the BMY21190-treated 
animals. The largest reduction in MAP occurred in the BMY21190 (1 mg/kg) group 
where, after 30 min of infusion, the MAP was reduced by 67% compared with the basal 
reading. After the first hyperemia, the LCX blood flow steadily declined to complete 
cessation in both control and BMY21190 groups. All control animals developed occlusive 
thrombi. BMY21190, infused at a dose of 1 mglkg, prevented the decline and eventual 
cessation of LCX blood flow characteristic in the control group. The left ventricular 
isometric force of the control dogs also declined slightly over the course of the experi- 
ment. The BMY21190-induced alterations in the decline of the left ventricular force were 
relatively small. A second infusion of BMY21190 after thrombotic occlusion of the LCX 
increased coronary blood flow. There also were marked differences between the 
BMY21190-treated and control animals with respect to intravascular thrombotic mass. 
These findings suggest that BMY21190 prevents occlusion of the LCX primarily by 
inhibiting thrombus formation at the site of intimal injury. 
The hemodynamic effects of BMY21190 are similar to those of other CAMP-PDE 
inhibitors. BMY21190 is a vasodilator which produces a reduction in arterial blood 
pressure and an increase in heart rate. BMY21190 and other closely related compounds 
TABLE 4. Hemodynamic effects of BMY21190 in a canine model of coronary 
artery thrombosis 
Vehicle 
(n = 9) 
~ 
BMY21190 
( 1  mglkg i.v.)(n = 6) 
Heart Rate (bpm) 
before 156.2 2 6.5 157.6 f 5.3 
after 161.1 f 8.0 215.3 * 11.6 
P ns P < 0.001 
before 104.8 f 12.9 108.6 ? 7.3 
after 106.2 f 4.1 72.5 ? 4.5 
P ns P < 0.001 
before 26.4 f 2.2 31.8 2 7.2 
after 26.2 f 2.1 40.5 * 8.9 
P ns P < 0.02 
before 74.5 2 11.3 71.6 f 9.7 
after 80. f 12.8 78.3 2 12.9 
P ns ns 
before 74.7 f 6.1 62.2 2 6.3 
after 78.3 2 6.5 64.6 2 8.6 
P ns ns 
Mean 5 SD. 
After = 30 min after drug administration. 
A P  arterial pressure; CBF: coronary blood flow; LAD: left anterior descending coronary artery; LCX: left 
circumflex coronary artery. 
Adapted from ref. 42. 
Mean AP (mm Hg) 
Mean CBF (mllmin) 
Tension-LAD (g) 
Tension-LCX (g) 
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have been shown to significantly inhibit platelet CAMP-PDE at low nanomolar doses (40). 
With systemic infusion at a dose of 1 mg/kg BMY21190 resulted in a marked inhibition 
of platelet activation measured ex vivo, with no significant change in ventricular con- 
tractile force. These pharmacological actions appeared to be the effect of a direct action 
on cardiac and vascular smooth muscle and were generally seen at doses higher than those 
required to produce significant effects on platelet aggregation (12,14,20). Amrinone and 
milrinone inhibit platelet activation in vitro with an efficiency that parallels their abilities 
to inhibit platelet CAMP-PDE and to increase myocardial contractile force (5,62,64). On 
the other hand, administration of BMY21190 did not cause any significant positive 
inotropic effect in the present canine model of coronary artery thrombosis. 
Effects of Intracoronary Administration of BMY21190 on the Coronary Blood 
Flow and Oxygen Content 
In order to elucidate the direct effect of BMY21190 on regional tension development 
and coronary blood flow and oxygen content, BMY21190 was administered directly into 
the coronary circulation in the canine heart (42). Male mongrel dogs were anesthetized 
with dial urethane (0.6 mg/kg i.v.) and ventilated under positive pressure with room air 
using a Harvard respirator pump. Tidal volume and respiratory rate were adjusted to 
maintain blood pH, PO,, and PCO, within normal limits (Instrument Lab., Blood Gas 
Analyzer, Micro 13). Distal to the first diagonal branch, 1 cm of the LAD was isolated 
from surrounding tissue by careful blunt dissection. Within this isolated region, an elec- 
tromagnetic flow probe was affixed. An intracoronary catheter for the drug infusion was 
inserted through the vessel wall of the LAD at a distance 3 mm distal to the electromag- 
netic flow probe. Patency of the intracoronary catheter was maintained throughout the 
experiment by infusing a 0.9% saline solution at a rate of 0.3 mumin. A segment of the 
great coronary vein was also isolated near the LAD area. An intracoronary venous cath- 
eter was placed in the great vein draining the LAD region to sample coronary venous 
blood. Another tube was inserted into the left atrial appendage (LA) for the withdrawal of 
arterial blood. Atrial pacing was performed by a Grass model S-44 stimulator and a Grass 
model PSIU-6 isolation unit. Propranolol (0.5 mVkg i.v.) was administered slowly to 
maintain a constant heart rate. BMY21190 or vehicle was rapidly injected into the cor- 
onary artery in 0.2 ml. Blood was periodically drawn from the LAD and LA. Atrial and 
venous oxygen contents were determined before each dose of BMY21190. 
As shown in Table 5, BMY21190 (0.01 and 0.03 mg/kg i.c.) increased the coronary 
blood flow significantly. The oxygen content of the left atrial appendage (A) did not 
change after BMY21190 (0.01 mg/kg i.c.) administration, but the oxygen content of the 
great coronary vein (V) in the BMY21190-distributed area increased significantly. 
BMY21190 (0.01 mgkg i.c.) reduced the oxygen A-V difference significantly (Table 6). 
BMY2 1 190 also caused significant coronary vasodilation without increasing myocardial 
oxygen consumption. 
As shown in Fig. 4 isometric tension in the area of the LAD was significantly increased 
after BMY21190 (0.01 mg/kg i.c.) administration. A large dose of BMY21190 (0.1 
mg/kg i.c.), however, produced a significant negative inotropic effect. This negative 
inotropic effect was significantly reversed by verapamil (0.5 mg/kg i.v.). Diltiazem (0.5 
mg/kg i.v.), however, did not affect this negative inotropism. In voltage clamp studies, 
milrinone (64), and amrinone (37,64) increased the amplitude of Ica. These agents pro- 
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TABLE 5 .  Mean coronary bloodflow change after intracoronary injection of BMY21190 in a 
propranolol-treated canine constant heart rate model with atrial pacing 
Changes of mean coronary blood flow 
(LAD; mUmin) 
Before After BMY21190 
BMY21190 (mgkg) 
0.01 (n = 10) 
0.03 (n = 9) 
0.1 (n = 10) 
29.9 t 9.5 
38.1 t 16.2 
4.14 2 16.7 
52.8 5 19.9* 
62.9 t 24.8*** 
55.8 5 28.5 
Mean 2 SD. 
* p < 0.05; *** p < 0.001 VS. before. 
BMY21190 was given by rapid intracoronary injection in a volume of 0.2 ml containing the above amounts 
Adapted from ref. 42. 
of drug. 
duced a positive inotropic effect and increased 45Ca uptake that is sensitive to verapamil 
(50). These results suggest that a large dose of BMY21190 induces an excessive calcium 
accumulation in the myocardial cells. 
Effect of BMY21190 on Coronary Artery Occlusion and Reperfusion 
Ischemic myocardial injury was produced in dogs by means of techniques detailed in 
previous publications (55). Male mongrel dogs were anesthetized with dial urethane, 
intubated, and ventilated with room air using a Harvard respirator. The LCX was isolated 
just before the first diagonal branch. LCX coronary blood flow was measured by placing 
an electromagnetic flow probe (Carolina Medical Electronics, Inc.) distal to an occlusive 
ligature. To limit reperfusion arrhythmias and myocardial hemorrhage, the occlusive 
ligature was adjusted so that basal coronary blood flow was not altered. After measure- 
ment of basal coronary blood flow, stenosis of the artery was produced by affixing a silk 
ligature around both the vessel and an 18- or 19-gauge needle. The degree of partial 
constriction was adjusted to reduce by at least 70% the hyperemic response to a 10-sec 
occlusion without altering basal flow. Five minutes later, myocardial ischemia was pro- 
duced by clamping the LCX flow completely for a period of 90 min. The mechanical 
TABLE 6.  Effect of intracoronary (LAD) administration of BMY21190 on the oxygen content of 
canine left atrial appendage and great coronary venous blood 
he-dNg Post BMY21190 
(n = 6) (0.01 mg/kg i.c.)(n = 6) 
Oxygen content (%) 
LAW) 
Great vein (V) 
A-V 
16.3 -+ 3.1 
4.2 5 1.1 
12.5 5 2.2 
15.4 t 5.4 
7.8 t 3.6* 
7.1 ? 2.6* 
Mean * SD. 
LA: left atrium; A-V: A-V difference 
Adapted from ref. 42. 
* p < 0.05 VS. PE-dntg. 
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FIG. 4. The effect of BMY21190 (0.01 mg/kg i.c.) on various cardiovascular parameters in the canine constant 
heart rate model. Adapted from ref. 42. 
occlusion was released gradually over a period of 30 min to prevent reperfusion induced 
ventricular fibrillation. Dogs remained anesthetized until sacrificed by electrical fibrilla- 
tion after the 6-hr reperfusion period. The experimental protocol consisted of a 90-min 
occlusion and 6-hr reperfusion of the LCX. 
While there is little doubt that platelets accumulate within infarcted myocardium 
(45,56), the role of platelets in the development of myocardial infarction is unclear. 
Platelets have been shown to form microemboli in ischemic myocardium (45) and to 
release vasoactive substances, including TXA, (25,63). Reperfusion produces a 10-fold 
increase in platelet accumulation, as compared to that found with permanent occlusion 
( 3 3 3 3 ) .  BMY21190 induced a significantly higher heart rate and lower mean arterial 
blood pressure than observed in the vehicle group. In general, the increase in pressure-rate 
products is an unfavorable action of CAMP-PDE inhibitors in patients with ischemic heart 
disease. Although BMY21190 induced a rise in heart rate, it had no significant effect on 
the pressure-rate products. Mean LCX coronary blood flow after reperfusion was signif- 
icantly less than the preocclusion flow in the vehicle group. BMY21190 administration, 
however, maintained coronary blood flow after reperfusion. There was a significant 
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difference between the vehicle and the BMY21190 groups with respect to mean coronary 
blood flow after reperfusion. 
REDUCTION OF ISCHEMIC MYOCARDIAL INJURY 
Postmortem Quantification of Infarct Size 
After a 90-min occlusion and 6-hr reperfusion of the LCX, myocardial infarct size was 
quantified by an in vitro dual perfusion technique previously described (55). Cannulae 
were inserted into the LCX immediately distal to the site of LCX occlusion and into the 
aorta above the coronary ostia. The LCX coronary bed was perfused with 1.5% triphenyl 
tetrazolium hydrochloride (TTC) in 20 mM potassium phosphate buffer (pH 7.4, 37°C). 
The aorta was perfused in a retrograde manner with 0.25% Evans blue dye. Both the LCX 
region and the remainder of the heart were simultaneously infused with their respective 
stains at a constant positive pressure of 100 mmHg for 5 min in a water bath (37°C). The 
stained heart was then sliced into six or seven sections, approximately 1 .O-cm thick, from 
apex to base. The area free of the blue dye indicated the area of the left ventricle at risk 
of infarction. The region of infarcted myocardium within the area at risk was demon- 
strated by the lack of staining of the tissue when perfused with TTC due to a loss of 
dehydrogenase enzymes which convert the colorless TTC to a red formazan precipitate. 
Analysis of Infarct Size 
More specifically, the upper surface of the transverse ventricular sections were traced 
carefully onto clear plastic sheets. In order to provide a permanent record of infarct 
morphology, the areas of each zone were measured by planimetry using a graphic tablet 
and Apple IIe computer (Apple Computer, Inc., Cupertino, CA, USA). A custom-made 
software program was used to calculate the masses of the infarct zone and the area at risk 
from the planimetered areas and the weights of each transverse ventricular section. Infarct 
size was calculated as a percentage of both the area at risk and the total left ventricle. 
Previous studies demonstrated that there is an excellent correlation between infarct size 
derived by the planimetric method and the direct gravimetric measurement (70). The 
measurement of infarct size using the TTC technique also correlated with the infarct size 
measured by histological examination. Transmural tissue blocks from the area at risk were 
obtained from three transverse sections of the hearts. 
There is increasing evidence that activated neutrophils cause myocardial injury during 
the reperfusion of ischemic myocardium (35,72). Reperfusion of ischemic myocardium 
may have both beneficial and detrimental effects on ischemic cells (7). Myocardial in- 
farction expands with the duration of coronary occlusion (29). Moreover, infarct size may 
be increased by reperfusion. After occlusion and reperfusion, the infiltration of neutro- 
phils into ischemic myocardium could exacerbate and promote myocardial damage (71). 
The invading neutrophils may injure the myocardial vasculature by generating oxygen 
free radicals (4734). While BMY20844 and BMY21190 increase the concentration of 
cAMP in leucocytes (38,43), free radical production is inhibited by the agents that 
produce cAMP accumulation (34). The increase in leukocyte cAMP will inhibit the 
activation of oxidative burst and chemotaxis. 
In order to elucidate the effect on infarct size. BMY21190 was administered before 
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reperfusion of the ischemic dog heart. Two dogs failed to complete the protocol due to 
intractable ventricular fibrillation after reperfusion. Thus, infarct size data are reported for 
six dogs treated with BMY21190 and for six dogs treated with vehicle (Table 7). As 
demonstrated previously (7 l), the gravimetric and planimetric methods of quantifying 
infarct size were in excellent agreement. For infarct size expressed as a percentage of the 
area at risk, the equation of liner regression was: planimetric = 1.05 (gravimetric) + 
0.08 (r = 0.99, SE = 2.43, n = 14). The data of infarct zone weight, risk zone weight, 
the ratio of infarct zone/left ventricular mass (LV), and area at risk are summarized in 
Table 7. Total LV mass and risk weight of BMY21190-treated dogs tended to decrease 
compared with those of vehicle-treated dogs. No significant difference, however, was 
demonstrated between them. Also, there was no significant difference between the area at 
risWLV in BMY21190-treated dogs and that in vehicle-treated dogs. As shown in Table 
7, in the control dogs (vehicle), mean infarct size was 62.4 ? 9.6% of the anatomic area 
at risk. In dogs receiving BMY21190, infarct size averaged 36.1 * 17.6% of the area at 
risk. Infarct size was significantly different from controls, whether expressed as grams of 
infarcted tissue or percentages of the area at risk (Table 7). 
Relationship Between Infarct Size and Myeloperoxidase Activity 
Because neutrophil infiltration is heterogenous (48), the transmural distribution of 
myeloperoxidase (MPO) activity across the ischemic region was studied in segments of 
tissue obtained from the infarct and risk zones. In addition, we examined the correlation 
between infarct size and MPO activity in a canine model undergoing a 90-min occlusion 
and 6-hr reperfusion. Bradley et al. (6) have utilized a spectrophotometric assay for the 
neutrophil-specific MPO enzyme to measure neutrophil accumulation in the ischemic 
myocardium. MPO serves as a quantitative indicator of neutrophil infiltration (48). MPO, 
contained within the azurophilic granules of the neutrophils, was liberated as follows. 
Myocardial tissue was frozen in liquid nitrogen and pulverized. Samples of myocardium 
TABLE 7 .  Effect of BMY21190 on canine infarct size after a 90-min occlusion and 6-hr 
reperfusion of the left circumflex coronary artery 
Vehicle BMY21190 
(n = 6) (1 mgkg i.v.)(n = 6)  
Gravimetric method 
Body weight (kg) 
Critical stenosis (%) 
LV weight (g) 
Area risk weight (g) 
Infarct zone weight (g) 
Planimetric method 
Area risWLV (%) 
Infarct zone/LV (%) 
Infarct zonelarea risk (%) 
15.4 -+ 0.9 
71.3 t 7.2 
93.4 2 13.4 
42.8 & 7.6 
24.1 2 6.7 
42.3 2 11.8 
27.4 t 11.4 
62.4 2 9.6 
14.0 ? 1.3 
60.6 2 6.0* 
79.1 2 39.3 
34.9 * 8.0 
13.0 ? 1.2* 
44.4 2 6.3 
16.1 2 7.8 
36.1 2 17.6* 
Mean i SD. 
* p  < 0.05 vs. vehicle. 
The quantification of the masses of the infarct zone, area at risk and left ventricle was done by both 
Adapted from ref. 43. 
gravimetric and planimetric methods. 
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(50-200 mg) were taken from the central infarct region, the noninfarcted tissue within the 
area at risk, and the overlapping border between the infarct region and the area at risk. 
Tissue was homogenized at 4°C in 0.5% hexadecyltrimethyl ammonium bromide (HTAB , 
Sigma Chemical Co.) buffered with 50 mM potassium phosphate (pH 6.0) with a polytron 
homogenizer (Kinernatica Ag, LittaulLucerne, Switzerland). The tissue suspensions were 
then sonicated for 10 sec on ice with a probe sonicator (Heat Systems-Ultrasonics, Inc., 
New York, NY, USA Model W-375). These samples were then centrifuged (20,000 g for 
15 min) and the supernatants were assayed for MPO activity. MPO was assayed spec- 
trophotometrically by adding 0.05 ml supernatant to 1.45 ml50 mM potassium phosphate 
buffer (pH 6.0) with 0.167 mg/ml o-dianisidine hydrochloride (Sigma Chemical Co.) and 
0.0005% hydrogen peroxide (Sigma Chemical Co.). The change in absorbency was 
measured at 460 nm with a Cary 210 Spectrophotometer (Cary Instruments, Monrovia, 
CA, USA). One unit of MPO (MP01100 mg tissue weight) activity was diluted to the 
amount of enzyme required to degrade 1 pmol hydrogen peroxide per minute at 25°C (48). 
As shown in Fig. 5, the highest MPO activity was found at the risk area where the 
activity at 6 hr was 0.40 U MP01100 mg tissue. Activity in the central infarct zone was 
0.30 U MP0/100 mg tissue. MPO activity (0.14 U/100 mg tissue) obtained from the area 
at risk treated by BMY (1 mg/kg i.v.), however, was significantly lower than that of the 
vehicle treated tissue (p < 0.05). The MPO activity in the infarct zone obtained from both 
groups was almost the same value suggesting that BMY21190 may be effective only on 
the area at risk. The relationship between MPO activity and infarct size was studied in 12 
dogs subjected to a 90-min occlusion and 6-hr reperfusion. Six of the infarcted dogs 
= 0 Vehicle group(n=6) BMY2119Ogroup(n=6) 
2 0.5 
* p < 0.05 vs Vehicle 
5 0.4 
i, mean & SE. - : - I  .- 
Non-infarcted zone Infarct zone Area at Risk 
FIG. 5. Effects of BMY21190 on tissue myeloperoxidase activity in a canine model of occlusion and reper- 
fusion. Adapted from ref. 43. 
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pretreated with BMY21190 (1 mgkg i.v.) were also included. The values show the infarct 
size (ratio area at risk) and the MPO activity obtained from the zone of area at risk. The 
ratio correlated well with the MPO activity (r = 0.683, p < 0.02). The relation was y = 
2.95 x + 11.5, including both groups (n = 12). 
Infarcted myocardium from BMY21190-treated dogs showed significantly lower MPO 
activity than that of vehicle-treated dogs. MPO activity in the area at risk treated with 
BMY21190 was significantly lower than that in vehicle-treated tissue. However, the MPO 
activity in the infarct zone obtained from both groups was almost the same. According to 
the protocol, BMY21190 was injected 45 min after the occlusion to prevent reperfusion 
injury. The infarction produced by this protocol may occur in two steps: first, it may occur 
simply through occlusion (13 g); secondly, it may develop through reperfusion injury (13 
to 24 g) induced by neutrophil infiltration. BMY21190 may be effective on the area at 
risk. In this protocol, BMY21190 does not affect the first step of infarct. For these 
reasons, the MPO activity in the infarct zone obtained from both groups might have been 
almost the same. 
INOTROPLC AND CHRONOTROPIC EFFECT OF BMY21190 IN ISOLATED 
RABBIT PAPILLARY MUSCLES AND ATRIAL PREPARATIONS 
BMY21190 was studied for its inotropic and chronotropic actions on rabbit isolated 
heart muscle preparations. At concentrations between lop7 and M, BMY21190 
showed a mild but significant positive inotropic effect (p < 0.05) of 113.6 ? 11.8% 
( lop6 M )  (n = 9) as compared with the vehicle control. Time-to-peak tension was 
decreased in a concentration-dependent manner (not significant). At a concentration of 
M ,  BMY21190 reduced the contractile force: 80.7 -+ 9.2% (p < 0.01 vs. vehicle 
group). In an in vivo study in large doses BMY21190 also induced a significant negative 
inotropic effect (42). This negative inotropic effect was partially reversed by verapamil. 
BMY21190 did not exert a positive chronotropic effect at concentrations between 
to M on rabbit isolated atrial preparations. In an in vivo study BMY21190 produced 
an increase in heart rate. BMY21190 caused a reduction in arterial blood pressure. The 
change of heart rate induced by BMY21190, therefore, may be a reflex tachycardia. Thus, 
BMY20844 and BMY21190 possess antithrombotic and moderate inotropic actions. In 
isolated cardiac tissues, PDE inhibitors exert a positive inotropic effect which is probably 
mediated by CAMP (1 1,49). This suggests that PDE I11 is the molecular target for some 
cardiotonic drugs (19). 
The effect of inotropic therapy on myocardial infarct size was not completely evalu- 
ated. Previous investigators have demonstrated, however, that dobutamine does not in- 
crease infarct size in humans (16) or dogs (32). Further studies are needed concerning the 
effects similar to those of dobutamine. 
It is suggested that the new inotropic vasodilator BMY21190 may have beneficial 
hemodynamic effects in patients with congestive heart failure. In numerous studies mil- 
rinone and enoximone have clearly been shown to improve hemodynamics in patients 
with congestive heart failure (27). The strength of milrinone and other type 111 PDE 
inhibitors as positive inotropes and vasorelaxants parallels their potency as cardiac and 
vascular type 111 PDE inhibitors (61). These data support the concept that a single mech- 
anism of action may account for the cardiotonic and vasodilator efficacy of milrinone and 
other type I11 PDE isozyme inhibitors (1 1). 
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MYOCARDIAL CAMP LEVELS 
The precise mechanism by which BMY21190 induces neutrophil infiltration is un- 
known. The type LII CAMP-PDE isozyme in the heart is the target of several agents (I 1) 
that increase contractile force (18) and decrease peripheral vascular resistance, as well as 
inhibit platelet aggregation. These agents produce an increase in cardiac inotropy and in 
45Ca uptake (37,50,64). The activation of oxidative metabolism is reported to be modu- 
lated by cyclic nucleotides and CAMP-accumulating agents (34). Free radical production 
is inhibited by exogenously added cAMP and agents which increase the levels of intra- 
cellular CAMP (34). 
We determined the level of myocardial cAMP content in the isolated rabbit heart. The 
hearts of male New Zealand white rabbits (1 .O-1.5 kg) were quickly isolated. Rabbit heart 
muscles were placed in contact with platinum electrodes and stimulated using a Grass 
stimulator (S88) set. After incubation, the experiments were performed as follows; the 
procedure was based on that as described by Sabina et al. (57). Prior to drug (or vehicle) 
addition and 10 min after the final concentration of BMY20844 and BMY21190, the heart 
muscle preparations were removed from the organ bath. The specimens were plunged and 
pressed between the jaws of “quick-freeze tongs,” which had been cooled within 5 sec 
using liquid nitrogen. The samples were ground to a fine powder with a mortar and pestle 
in an ice bucket surrounded by dry ice in acetone. The powder was centrifuged at 10,000 
X 4°C for 15 min. To aliquots of 100 p1 of supernatant, 1 ml of water-saturated ether was 
added and the mixtures were centrifuged under the same conditions. Ether extraction was 
repeated three more times. After this procedure, the aliquots of supernatant were boiled 
for 1 min. Radioimmunoassay of tissue CAMP (26) was canied out after acetylation using 
triethylamine and acetic anhydride. As shown in Table 8, both BMY20844 ( lop6 M) and 
BMY21190 ( lop6 M) significantly increased myocardial cAMP content compared with 
that of the vehicle-treated rabbit heart. These drugs have a significant positive inotropic 
effect on isolated rabbit papillary muscle, suggesting a relationship between the positive 
inotropic action and the tissue level of CAMP. BMY21190 induces both cAMP and 
calcium accumulation in the myocardial cells and may protect them from exposure to 
oxygen radicals. 
SUMMARY 
Compounds containing the imidazoquinoline nucleus are a new class of potent broad- 
spectrum inhibitors of platelet aggregation (38). BMY21190 is an ether-linked side chain 
derivative with a simply substituted imidazoquinoline. These compounds are potent in- 
hibitors of platelet cAMP PDE (ICs0 lO-*M) but have little effect on platelet homogenate 
cGMP PDE (ICs0 > 10-5M) (8). BMY21190 was evaluated for its ability to modify the 
development of experimental thrombosis resulting from anodal current injury (100 pA for 
6 hr) to the intimal surface of the left circumflex coronary artery (LCX) in the anesthetized 
dog (42). After a 30-min administration of BMY21190, heart rate and mean coronary 
blood flow were increased significantly and mean arterial pressure was decreased. The 
myocardial tension of the LAD and LCX areas, however, did not change significantly 
after BMY21190 infusion. During LCX stimulation, the first LCX occlusion and the 
hyperemic reaction occurred significantly earlier in the control group than in the 
BMY21190 group. Compared with the controls, BMY21190 treatment reduced the de- 
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TABLE 8. Myocardial CAMP levels of BMY20844- and BMY2II9O-treated rabbit heart 
Vehicle BMY20844 BMY21190 
(n = 8) M (n = 7) M (n = 7) 
cAMP contents (p moles/mg tissue) 
Right ventricle 0.524 -+ 0.190 0.793 -+ 0.191* 0.952 2 0.315* 
Left ventricle 0.314 2 0.166 0.545 2 0.423 0.911 -+ 0.276** 
Mean * SD. 
* p < 0.05, ** p < 0.01 vs. vehicle. 
n = numbers of rabbits. 
Dose M) shows the final concentration in the organ bath (Minami, Dnscol and Lucchesi, unpublished 
data). 
velopment of LCX thrombus mass. In ex vivo studies, platelet aggregation in response to 
arachidonic acid, ADP, or collagen was inhibited by BMY21190. 
The precise mechanism by which BMY21190 induces platelet inhibition is unknown. 
Agents capable of increasing intraplatelet accumulation of cAMP effectively inhibit plate- 
let aggregation induced by broad-spectrum agonists (8,41,60). Elevation of platelet 
cAMP leads to phosphorylation of platelet myosin light chain kinase by a CAMP- 
dependent protein kinase (22). The CAMP-mediated phosphorylated and inactivated form 
of myosin reduces actin-myosin interaction, platelet contraction, and granule secretion 
(22). 
The effect of BMY21190 on infarct size was also evaluated using a canine ischemic 
model with 90-min occlusion and 6-hr reperfusion of the left coronary artery (42). The 
infarct zone/area at risk of the BMY21190 group was significantly smaller than that of the 
vehicle group. Myeloperoxidase activity, an indicator of neutrophil infiltration, measured 
in the area at risk from hearts of the BMY21190-treated group was significantly lower 
than that in the vehicle treated tissue. BMY21190 may reduce the infarct size partly 
through the inhibition of neutrophil infiltration in the canine model. BMY21190 achieved 
a desired antithrombotic effect without thrombocytopenic side effects. In addition, the 
strong coronary vasodilating and mild inotropic actions of BMY21190 had a significant 
impact on cardiac hemodynamics. BMY21190 and BMY20844 represent the first com- 
pounds of this series to be selected for clinical testing (40). BMY20844 was selected from 
this series as a candidate for clinical assessment and has been studied in some detail at the 
biochemical (60) and pharmacological levels (8). 
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